Home News Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

by admin
0 views

TOKYO, Nov 24, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022.Key data Presentations for perampanel include the:
– Results from a post hoc analysis of the phase III clinical trial (FREEDOM/342), which evaluated long-term efficacy of perampanel monotherapy by seizure type in the open-label extension (52 weeks) for epilepsy patients with focal-onset seizures (FOS), ≥ 12 years of age without prior treatment history (poster number: 2.228)
– Real-world pooled analyses of perampanel for pediatric patients (poster number: 1.310),
adolescent patients (poster number: 1.313) and elderly patients (poster number: 1.312)
– Results from a post hoc analysis of two phase III open-label extension (OLEx) studies, Study 307 and Study 335 OLEx, evaluating the long-term efficacy and safety of adjunctive perampanel in a subgroup of older adult patients aged ≥ 60 years (poster number: 1.291)

“With 34 poster presentations planned for this year’s AES Meeting, we look forward to furthering our understanding of the results that may impact overall care in epilepsy,” said Ivan Cheung, Senior Vice President Global Alzheimer’s Disease Officer President, Americas Region, Eisai Co., Ltd., “We remain focused on addressing the diverse needs of patients with epilepsy and their families.”

Perampanel is a first-in-class AED discovered by Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper- excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. The agent is currently approved for partial-onset seizures (with or without secondarily generalized seizures) in over 70 countries including Japan, the United States, China and other countries in Europe and in Asia. The agent is currently approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including Japan, the United States, and other countries in Europe and in Asia.

Eisai considers neurology, including epilepsy, a therapeutic area of focus. Eisai pursues its mission to provide “seizure freedom” to a greater number of patients with epilepsy. Eisai remains committed further to addressing the diverse needs of, and increasing the benefits provided to, patients with epilepsy and their families

For more information, visit www.eisai.com/news/2022/pdf/enews202281pdf.pdf.

Topic: Press release summary

Source: Eisai

Sectors: BioTech

http://www.acnnewswire.com

From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Source : ACN Newswire

Related Articles

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting https://www.lacompagniedesbambous.com   https://mesothelioma-info.info   https://www.enigmesghisdiem.fr   https://paris-pictures.org   https://www.intellinews.info  
--
ASICS Gel 210 Not Out Chaussure De Cricket – SS15 *  Pandora Anneau Heart Delicate 190995CZ-52 Argent et zircons *  Justin Fields unsure about status for Week 13 vs. Packers *  * Monkeypox spreading in ‘cluster events,’ but vaccines can help stop it, local health officials say – CNN *  Steph Curry delivers NBA Finals jab at Grant Williams in ESPYs monologue *  Formula 1, niente Gp in Cina nel 2023: la Federazione pensa a Portimao – Sport – Formula1 *  The Habsburg Empire: A New History *  Climatiseur Mobile Ventilateur De Tour Refroidisseur d’air Froid Climatiseur Portable Mobile Évaporatif Intelligente… *  * FDA Requests More Restrictions on Ovarian Cancer Drugs *  La Maison Courtine, 157, avenue du Maine 75014 Paris *  https://instruments-demusique.com   https://www.politique-france.com   https://marionnettes.info   https://www.le-noeud-papillon.com   https://www.marionnettes-a-mains.com/   https://www.campingetrandonnee.com/   https://monmaillotdebain.com   https://www.village-global.com   Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting *Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

news7.asia Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting